Although insulin sensitizing agents including thiazolidinediones and biguanides have been clinically used in the majority of T2D, the treatment of the diabetic patients with chronic liver diseases is inapplicable, because of the impaired liver function and the potential hepatotoxicity of those conventional drugs. The gene discussed is INS; the disease is type 2 diabetes mellitus.